Last reviewed · How we verify
NCT04986254: PNEUDOS
PNEUmonia DOSing in Critically Ill Patients (PNEUDOS)
trial testing Blood sampling in Pneumonia in 179 participants. Completed in 31 January 2024.
31 January 2024
Quick facts
| Lead sponsor | The University of Queensland |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 179 |
| Start date | 17 October 2019 |
| Primary completion | 31 January 2024 |
| Estimated completion | 31 January 2024 |
| Sites | 6 locations across Belgium, Malaysia, Hong Kong, France, Australia |
Drugs / interventions tested
- Blood sampling — full drug profile →
- Epithelial lining fluid sampling
- Urine sampling — full drug profile →
- Study antibiotics include benzylpenicillin, ceftriaxone, meropenem, and piperacillin/tazobactam — full drug profile →
Conditions studied
- Pneumonia — all drugs for Pneumonia →
Sponsor
The University of Queensland
Who can join
18 and older, any sex, with Pneumonia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Pneumonia is the most common infection in intensive care unit (ICU) patients and occurs in 10% of all ICU admissions. Unfortunately, ICU patient outcomes remain poor with a high mortality rate associated with pneumonia despite recent therapeutic advances. Previous studies of antibiotics used in ICU patients, which includes ceftriaxone, meropenem and piperacillin/tazobactam, have quantified major differences in pharmacokinetics (PK) between ICU and non-ICU patients, with ICU patients displaying a unique spectrum of plasma concentration-time profiles. These PK differences can lead to suboptimal antibiotic concentrations in blood, which have been associated with a reduced likelihood of clinical cure for pneumonia. Furthermore, highlighting the importance of optimised dosing for pneumonia is that multi-drug resistant (MDR) pathogens emerge during antibiotic therapy in approximately half of the ICU patients, frequently emerging from the lung. Previous work has highlighted how infection site concentrations determine patient outcome. For pneumonia, the infection site is best described as the epithelial lining fluid (ELF) in the lung. Although optimal antibiotic therapy should be considered a priority for ICU patients with pneumonia to improve the persisting poor outcomes, the dosing regimens that can achieve therapeutic concentrations at the infection site (i.e., ELF) in ICU patients with pneumonia remain unknown. The PNEUDOS study aims to address this significant knowledge gap by defining novel individualised dosing regimens that can maximise antibiotic efficacy by achieving therapeutic concentrations in the blood and ELF of ICU patients with pneumonia. These dosing regimens can then be validated in future clinical trials.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04986254
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Blood sampling
Trials testing the same drug.
- NCT07372859 — Women's Heart: Impact of Ultra-endurance and Hormonal Profile on Cardiac and Systemic Inflammatory Parameters in Female · NA · not yet recruiting
- NCT07237984 — Colorectal Omics and ofCS Proteoglycans (COCO) in Screening and a Diagnostic Pathway · not yet recruiting
- NCT06544018 — Circadian Rhythm Deregulation in Patients With CAPS · NA · recruiting
- NCT07245550 — Thyroid and Adrenal Disorders in ICU · not yet recruiting
- NCT07033091 — Prevalence of Human Papillomavirus (HPV) in a Healthy Population: A Feasibility Study of Oropharyngeal Cancer Screening · NA · recruiting
Other recruiting trials for Pneumonia
Currently open trials in the same condition.
- NCT07453966 — Efficacy and Safety of Intrapulmonary Percussive Ventilation in Patients With Pulmonary Infection Receiving Invasive Mec · NA · recruiting
- NCT07251465 — A Study to Learn How Effective is PCV20 to Help Stop Adults Who Have a Higher Chance of Getting Pneumonia · active not recruiting
- NCT07311343 — Oral Hygiene and Prophylactic Antibiotics to Prevent Intracerebral Hemorrhage Associated Pneumonia · Phase 4 · recruiting
- NCT07298889 — High PEEP in Noninvasive Ventilation Patients With Pneumonia or ARDS · NA · recruiting
- NCT06911658 — Infectious Complications After Esophagectomy · recruiting
Other The University of Queensland trials
Trials by the same sponsor.
- NCT06120673 — REmission in Membranous Nephropathy International Trial (REMIT) · Phase 3 · withdrawn
- NCT06642597 — STarting incrEmental Prescription of Peritoneal Dialysis · NA · recruiting
- NCT07114354 — Enhancing Utility of Neuropsychological Evaluation for Earlier and Effective Diagnosis of Dementia in Parkinson's Diseas · NA · not yet recruiting
- NCT06806709 — Reducing Blood Culture Contamination With the Use of a Needle-less Blood Draw Device (The PIVO Trial) · NA · recruiting
- NCT06882239 — SPINEPASS: SPINE Self-management Techniques for Persistent Headache After Concussion: Physical Therapy Targeting Autonom · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04986254 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The University of Queensland
- Last refreshed: 28 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04986254.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing